Dr. Keith Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. His research and clinical focus is on melanoma, particularly targeted therapies.

Keith serves as senior editor of Clinical Cancer Research and a member of the editorial board for many other publications, such as Cancer Discovery, Journal of Clinical Oncology, Cancer, Pigment Cell, and Melanoma Biology. He has acted as first author for three New England Journal of Medicine papers. He has been the principal investigator of many clinical trials, including first-in-human trials of novel targeted therapies and two NCI cooperative group trials.

Keith earned his undergraduate degree from Yale University in 1993 and his M.D. from Johns Hopkins University in 1997. He currently lives in Boston.